Objective:

To summarize the presentations and findings from the Temple Lung Center at the American Thoracic Society's 2026 International Conference.

Approach:

• Conference Overview: The conference featured over 70 abstracts presented by faculty and fellows from the Temple Lung Center, covering various topics in pulmonary medicine.
• Key Presentations: Highlighted presentations included studies on COPD therapeutics, lung cancer screening, pulmonary hypertension, and the role of artificial intelligence in diagnostics.

Key Findings:

• Data from a Phase 2 trial demonstrated that pegtarazimod was safe and reduced supplemental oxygen needs in COPD patients.
• Pooled results from Phase III trials showed that mepolizumab significantly reduced hospitalization risk for COPD exacerbations across a wide patient spectrum.
• Elevated eosinophil counts near conception were linked to increased asthma exacerbations during pregnancy.
• Baseline 6-minute walk test heart rate metrics correlated with higher hospital utilization in COPD patients.
• Inhaled treprostinil preserved lung function in adults with idiopathic pulmonary fibrosis in a Phase 3 trial.
• Disparities in survival rates after lung transplant for SARD-ILD were observed based on race and ethnicity.
• Higher corticosteroid doses were associated with shorter hospitalizations in acute exacerbation survivors of SARD-ILD.
• Pre-procedural CT analysis identified key factors correlating with pneumothorax risk after bronchoscopic lung volume reduction.

Limitations:

• The need for prospective studies to validate findings in larger cohorts was noted.
• Disparities in access and outcomes suggest broader systemic issues that require further investigation.

Conclusion:

The conference showcased significant research contributions from the Temple Lung Center, emphasizing the importance of ongoing studies in pulmonary medicine.